JP2016530279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530279A5 JP2016530279A5 JP2016537894A JP2016537894A JP2016530279A5 JP 2016530279 A5 JP2016530279 A5 JP 2016530279A5 JP 2016537894 A JP2016537894 A JP 2016537894A JP 2016537894 A JP2016537894 A JP 2016537894A JP 2016530279 A5 JP2016530279 A5 JP 2016530279A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- sustained release
- compound
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 58
- 150000001875 compounds Chemical class 0.000 claims description 54
- 239000008194 pharmaceutical composition Substances 0.000 claims description 36
- 238000013268 sustained release Methods 0.000 claims description 23
- 239000012730 sustained-release form Substances 0.000 claims description 23
- 230000036470 plasma concentration Effects 0.000 claims description 22
- 238000009472 formulation Methods 0.000 claims description 20
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 12
- 231100000057 systemic toxicity Toxicity 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 229940109239 creatinine Drugs 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 5
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 208000006289 Rett Syndrome Diseases 0.000 claims description 4
- 208000017849 acquired lipodystrophy Diseases 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 4
- 208000006132 lipodystrophy Diseases 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 206010053857 partial lipodystrophy Diseases 0.000 claims description 4
- 231100000816 toxic dose Toxicity 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 208000024412 Friedreich ataxia Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 241000406668 Loxodonta cyclotis Species 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019162622A JP6913137B2 (ja) | 2013-08-30 | 2019-09-06 | 新規２，４−ジニトロフェノール製剤およびその使用法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361872294P | 2013-08-30 | 2013-08-30 | |
| US61/872,294 | 2013-08-30 | ||
| US201361919003P | 2013-12-20 | 2013-12-20 | |
| US61/919,003 | 2013-12-20 | ||
| PCT/US2014/053406 WO2015031756A1 (en) | 2013-08-30 | 2014-08-29 | Novel 2,4-dinitrophenol formulations and methods using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019162622A Division JP6913137B2 (ja) | 2013-08-30 | 2019-09-06 | 新規２，４−ジニトロフェノール製剤およびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530279A JP2016530279A (ja) | 2016-09-29 |
| JP2016530279A5 true JP2016530279A5 (enExample) | 2017-09-07 |
| JP6706204B2 JP6706204B2 (ja) | 2020-06-03 |
Family
ID=52587363
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537894A Active JP6706204B2 (ja) | 2013-08-30 | 2014-08-29 | 新規２，４−ジニトロフェノール製剤およびその使用法 |
| JP2019162622A Active JP6913137B2 (ja) | 2013-08-30 | 2019-09-06 | 新規２，４−ジニトロフェノール製剤およびその使用法 |
| JP2021113956A Active JP7359809B2 (ja) | 2013-08-30 | 2021-07-09 | 新規２，４－ジニトロフェノール製剤およびその使用法 |
| JP2023127746A Pending JP2023133603A (ja) | 2013-08-30 | 2023-08-04 | 新規２，４－ジニトロフェノール製剤およびその使用法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019162622A Active JP6913137B2 (ja) | 2013-08-30 | 2019-09-06 | 新規２，４−ジニトロフェノール製剤およびその使用法 |
| JP2021113956A Active JP7359809B2 (ja) | 2013-08-30 | 2021-07-09 | 新規２，４－ジニトロフェノール製剤およびその使用法 |
| JP2023127746A Pending JP2023133603A (ja) | 2013-08-30 | 2023-08-04 | 新規２，４－ジニトロフェノール製剤およびその使用法 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US10786466B2 (enExample) |
| EP (1) | EP3038611B1 (enExample) |
| JP (4) | JP6706204B2 (enExample) |
| CN (2) | CN110302385A (enExample) |
| WO (1) | WO2015031756A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10786466B2 (en) * | 2013-08-30 | 2020-09-29 | Yale University | 2,4-dinitrophenol formulations and methods using same |
| HK1247101A1 (zh) * | 2015-01-22 | 2018-09-21 | Mitochon Pharmaceuticals, Inc. | 用於治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达 |
| DE102015016801A1 (de) * | 2015-12-23 | 2017-06-29 | Christian Windisch | Chemotherapeutisches Verfahren zur Behandlung maliger Geschwülste durch "Entkopplung" der oxidativen Phosphorilierung ("Krebsatmung") in aerob glycolysierenden Zellen (Krebszellen) |
| CN115227685A (zh) * | 2016-03-07 | 2022-10-25 | 米托充制药公司 | 疾病的dnp和dnp前药治疗 |
| KR102579648B1 (ko) | 2017-01-06 | 2023-09-18 | 리부스 파마슈티칼스, 인크. | 신규한 페닐 유도체 |
| WO2019217164A1 (en) * | 2018-05-09 | 2019-11-14 | Reyoung Corporation | Compositions and methods for treating cancer and other diseases |
| WO2020257283A1 (en) | 2019-06-18 | 2020-12-24 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| CN110237033A (zh) * | 2019-07-30 | 2019-09-17 | 成都医学院 | 一种2,4二硝基苯酚注射液及其制备方法和用途 |
| CN110302154B (zh) * | 2019-07-30 | 2021-09-10 | 成都医学院 | 一种2,4-二硝基苯酚脂肪乳及其制备方法和用途 |
| CN113045428B (zh) * | 2019-12-26 | 2022-04-22 | 中国农业大学 | 化合物及其在减脂中的用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2183589A (en) | 1939-12-19 | Derivatives of compounds of the | ||
| CA774573A (en) | 1967-12-26 | Sehring Richard | Derivatives of 2-hydroxy-3,5-dinitrobenzyl alcohol | |
| US1695656A (en) | 1927-03-10 | 1928-12-18 | Firm Gehe & Co A G | Method of producing narcotica |
| US3081224A (en) | 1959-01-21 | 1963-03-12 | American Cyanamid Co | Methods of removing helminths employing halogenated nitrophenols and their derivatives |
| NL301998A (enExample) | 1962-12-27 | 1900-01-01 | ||
| DE3313905A1 (de) | 1983-04-16 | 1984-10-25 | Henkel KGaA, 4000 Düsseldorf | Neue 2.4-diaminophenolether als kuppler fuer oxidationshaarfaerbemittel |
| DE3515339A1 (de) | 1985-04-27 | 1986-10-30 | Cassella Ag, 6000 Frankfurt | Verfahren zur herstellung von 2,4-dinitrophenylethern |
| CN1011660B (zh) * | 1986-04-23 | 1991-02-20 | 吴佩璇 | 一种含三硝基苯、田螺的药品合成方法 |
| US5078908A (en) | 1989-10-02 | 1992-01-07 | Allergan, Inc. | Methods for generating chlorine dioxide and compositions for disinfecting |
| US5169645A (en) | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
| IN192400B (enExample) * | 1995-06-14 | 2004-04-10 | Council Scient Ind Res | |
| US5866514A (en) | 1995-07-11 | 1999-02-02 | Nippon Petrochemicals Company, Limited | Pesticidal composition to noxious organisms |
| JP2003526694A (ja) | 1998-04-24 | 2003-09-09 | イーストマン ケミカル カンパニー | セルロースエステルと機能性添加剤との共沈及びそれによって得られる組成物 |
| WO2000006143A1 (en) * | 1998-07-27 | 2000-02-10 | Texas Pharmaceuticals, Inc. | Chemically induced intracellular hyperthermia |
| US6664297B1 (en) | 2000-10-18 | 2003-12-16 | Universidade Federal Do Rio De Janeiro | Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol |
| EP1929998A3 (en) * | 2001-09-21 | 2008-11-26 | Egalet A/S | Controlled release solid dispersions of carvedilol |
| EP1545477A4 (en) | 2002-09-13 | 2006-11-22 | Cydex Inc | CAPSULES CONTAINING AQUEOUS FILLING COMPOSITIONS STABILIZED WITH DERIVED CYCLODEXTRIN |
| ATE468114T1 (de) | 2002-11-08 | 2010-06-15 | High Point Pharmaceuticals Llc | Sichere chemische entkuppler zur behandlung von fettsucht |
| US8569356B2 (en) | 2005-10-25 | 2013-10-29 | University Of Florida Research Foundation, Inc. | Cyclin dependent kinase inhibitors |
| EP2196453A1 (en) | 2008-12-10 | 2010-06-16 | Cellvir | Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents |
| WO2011053825A2 (en) * | 2009-10-30 | 2011-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment or prevention of mitochondrial diseases |
| JP2013209295A (ja) * | 2010-10-13 | 2013-10-10 | Takeda Chem Ind Ltd | ペプチド誘導体 |
| US10786466B2 (en) | 2013-08-30 | 2020-09-29 | Yale University | 2,4-dinitrophenol formulations and methods using same |
-
2014
- 2014-08-29 US US14/911,322 patent/US10786466B2/en active Active
- 2014-08-29 EP EP14839060.2A patent/EP3038611B1/en active Active
- 2014-08-29 CN CN201910726120.2A patent/CN110302385A/zh active Pending
- 2014-08-29 JP JP2016537894A patent/JP6706204B2/ja active Active
- 2014-08-29 WO PCT/US2014/053406 patent/WO2015031756A1/en not_active Ceased
- 2014-08-29 CN CN201480059363.0A patent/CN105682653B/zh active Active
-
2019
- 2019-09-06 JP JP2019162622A patent/JP6913137B2/ja active Active
-
2020
- 2020-07-22 US US16/936,316 patent/US11433033B2/en active Active
-
2021
- 2021-07-09 JP JP2021113956A patent/JP7359809B2/ja active Active
-
2022
- 2022-05-16 US US17/663,586 patent/US11883369B2/en active Active
-
2023
- 2023-08-04 JP JP2023127746A patent/JP2023133603A/ja active Pending
-
2024
- 2024-08-22 US US18/812,381 patent/US20250228793A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wedemeyer et al. | Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection | |
| WO2008085484A3 (en) | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid | |
| JP6913137B2 (ja) | 新規２，４−ジニトロフェノール製剤およびその使用法 | |
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| ME02662B (me) | Niskofrekventna terapija glatiramer acetatom | |
| JP2015519329A5 (enExample) | ||
| NO20084199L (no) | Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom | |
| EP3684344B1 (en) | Delayed release deferiprone tablets and methods of using the same | |
| JP7651620B2 (ja) | 経口リファマイシンｓｖ組成物 | |
| JP7175897B2 (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| JP2020526553A5 (enExample) | ||
| JP2013508289A5 (enExample) | ||
| JP6986445B2 (ja) | １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| JP2019501226A5 (enExample) | ||
| JP2020500864A5 (enExample) | ||
| RU2019110779A (ru) | Новые схемы введения агонистов fxr | |
| EA201001100A1 (ru) | Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение | |
| JP2016505050A5 (enExample) | ||
| RU2013105504A (ru) | Лекарственное средство для предотвращения и/или лечения гепатоклеточной карциномы | |
| JP2023510341A5 (ja) | ナルブフィン治療可能障害を治療するために投与されるナルブフィン製剤 | |
| HRP20250052T1 (hr) | Postupak liječenja multiple skleroze | |
| JP2019507785A5 (enExample) | ||
| JP2011500650A5 (enExample) | ||
| JP2019535830A5 (enExample) |